The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications

AbstractIntroductionParkinson's disease (PD) is a neurodegenerative condition associated with aging characterized by loss of dopamine-producing neurons in the substantia nigra pars compacta and a reduction in dopamine levels in the striatum. PD is commonly treated using dopamine-replacement med...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the neurological sciences 2019-01, Vol.396, p.262-265
Hauptverfasser: Bay, Allison A, Hart, Ariel R, Michael Caudle, W, Corcos, Daniel M, Hackney, Madeleine E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 265
container_issue
container_start_page 262
container_title Journal of the neurological sciences
container_volume 396
creator Bay, Allison A
Hart, Ariel R
Michael Caudle, W
Corcos, Daniel M
Hackney, Madeleine E
description AbstractIntroductionParkinson's disease (PD) is a neurodegenerative condition associated with aging characterized by loss of dopamine-producing neurons in the substantia nigra pars compacta and a reduction in dopamine levels in the striatum. PD is commonly treated using dopamine-replacement medication called levodopa. Levodopa has decreasing efficacy over time. Periods when levodopa is not effective at controlling symptoms of PD are called “OFF-time” or “medication-related motor fluctuations,” (MRMF). One characteristic of PD is unilateral side of symptom onset. Previous studies have found that side of onset was associated with differential motor and cognitive PD-related symptoms. The main study objective was to examine differences in left and right onset PD patients and OFF-time as measured by the Movement Disorders Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part IV Sum Score and Part IV item scores. Methods64 individuals with mild-moderate PD (age: M(SD) = 68.72 (8.88)), years with PD: M(SD) = 6.61 (5.05); Hoehn and Yahr stage Med (1st, 3rd quartile) = 2.0 (2.0, 3.0) were assessed with the MDS-UPDRS parts I-IV. We conducted two-tailed independent sample t-tests to examine the differences between PD patients with left versus right onset. ResultsRight onset PD was significantly associated with more overall MRMF (p = 0.01), more OFF-time (p = 0.04), greater impact of motor fluctuations on daily life (p = 0.02) and more complex (unpredictable) MRMF (p = 0.01). ConclusionPeople with right onset PD have more complications with levodopa treatment. Alternative and/or adjuvant treatments to levodopa may be particularly beneficial for those with right onset PD.
doi_str_mv 10.1016/j.jns.2018.12.002
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6324940</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022510X1830488X</els_id><sourcerecordid>2155162534</sourcerecordid><originalsourceid>FETCH-LOGICAL-c532t-89929b13995de93f64541fb5556d7335d30d27e5f7b3dca07d66674ee0c677633</originalsourceid><addsrcrecordid>eNp9ks9u1DAQxiMEokvhAbgg3-CSxY7jxAGpUtXyp1IrKrZFvVlee0K9Tezg8RbtA_DeeNlSAQdOluzv-2Y8vymK54zOGWXN69V85XFeUSbnrJpTWj0oZky2shRS8ofFLN9UpWD0aq94griilDZSdo-LPU4FbxvOZsWPi2sgGjEYp5MLniwhfQfw5FzHG-cx-JdIrEPQCAQ345TCSNBZKENfBo-QiPaWTBD7EEftDZAcknLo2fGivDw__rwgaPQAZNIxkZMvb8hZSCESE8ZpcOZXUXxaPOr1gPDs7twvLt-_uzj6WJ5--nBydHhaGsGrVMquq7ol410nLHS8b2pRs34phGhsy7mwnNqqBdG3S26Npq1tmqatAahp2vxfvl8c7HKn9XIEa8CnqAc1RTfquFFBO_X3i3fX6mu4VQ2v6q6mOeDVXUAM39aASY0ODQyD9hDWqComBGsqwessZTupiQExQn9fhlG1xadWKuNTW3yKVSrDyp4Xf_Z37_jNKwve7gSQp3TrICo0DvLUrYtgkrLB_Tf-4B-3GZzPEIYb2ACuwjr6PH7FFGaDWmz3Z7s-THJaS3nFfwIAbcHW</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2155162534</pqid></control><display><type>article</type><title>The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Bay, Allison A ; Hart, Ariel R ; Michael Caudle, W ; Corcos, Daniel M ; Hackney, Madeleine E</creator><creatorcontrib>Bay, Allison A ; Hart, Ariel R ; Michael Caudle, W ; Corcos, Daniel M ; Hackney, Madeleine E</creatorcontrib><description>AbstractIntroductionParkinson's disease (PD) is a neurodegenerative condition associated with aging characterized by loss of dopamine-producing neurons in the substantia nigra pars compacta and a reduction in dopamine levels in the striatum. PD is commonly treated using dopamine-replacement medication called levodopa. Levodopa has decreasing efficacy over time. Periods when levodopa is not effective at controlling symptoms of PD are called “OFF-time” or “medication-related motor fluctuations,” (MRMF). One characteristic of PD is unilateral side of symptom onset. Previous studies have found that side of onset was associated with differential motor and cognitive PD-related symptoms. The main study objective was to examine differences in left and right onset PD patients and OFF-time as measured by the Movement Disorders Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part IV Sum Score and Part IV item scores. Methods64 individuals with mild-moderate PD (age: M(SD) = 68.72 (8.88)), years with PD: M(SD) = 6.61 (5.05); Hoehn and Yahr stage Med (1st, 3rd quartile) = 2.0 (2.0, 3.0) were assessed with the MDS-UPDRS parts I-IV. We conducted two-tailed independent sample t-tests to examine the differences between PD patients with left versus right onset. ResultsRight onset PD was significantly associated with more overall MRMF (p = 0.01), more OFF-time (p = 0.04), greater impact of motor fluctuations on daily life (p = 0.02) and more complex (unpredictable) MRMF (p = 0.01). ConclusionPeople with right onset PD have more complications with levodopa treatment. Alternative and/or adjuvant treatments to levodopa may be particularly beneficial for those with right onset PD.</description><identifier>ISSN: 0022-510X</identifier><identifier>EISSN: 1878-5883</identifier><identifier>DOI: 10.1016/j.jns.2018.12.002</identifier><identifier>PMID: 30537631</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Aged ; Aged, 80 and over ; Antiparkinson Agents - therapeutic use ; Disease Progression ; Female ; Functional Laterality - drug effects ; Functional Laterality - physiology ; Humans ; Levodopa ; Levodopa - therapeutic use ; Male ; MDS-UPDRS ; Mental Status and Dementia Tests ; Middle Aged ; Neurology ; OFF-time ; Parkinson Disease - diagnosis ; Parkinson Disease - drug therapy ; Parkinson Disease - physiopathology ; Parkinson Disease, Secondary - diagnosis ; Parkinson's disease ; Severity of Illness Index ; Side-of-onset ; Treatment</subject><ispartof>Journal of the neurological sciences, 2019-01, Vol.396, p.262-265</ispartof><rights>2018</rights><rights>Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c532t-89929b13995de93f64541fb5556d7335d30d27e5f7b3dca07d66674ee0c677633</citedby><cites>FETCH-LOGICAL-c532t-89929b13995de93f64541fb5556d7335d30d27e5f7b3dca07d66674ee0c677633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0022510X1830488X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30537631$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bay, Allison A</creatorcontrib><creatorcontrib>Hart, Ariel R</creatorcontrib><creatorcontrib>Michael Caudle, W</creatorcontrib><creatorcontrib>Corcos, Daniel M</creatorcontrib><creatorcontrib>Hackney, Madeleine E</creatorcontrib><title>The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications</title><title>Journal of the neurological sciences</title><addtitle>J Neurol Sci</addtitle><description>AbstractIntroductionParkinson's disease (PD) is a neurodegenerative condition associated with aging characterized by loss of dopamine-producing neurons in the substantia nigra pars compacta and a reduction in dopamine levels in the striatum. PD is commonly treated using dopamine-replacement medication called levodopa. Levodopa has decreasing efficacy over time. Periods when levodopa is not effective at controlling symptoms of PD are called “OFF-time” or “medication-related motor fluctuations,” (MRMF). One characteristic of PD is unilateral side of symptom onset. Previous studies have found that side of onset was associated with differential motor and cognitive PD-related symptoms. The main study objective was to examine differences in left and right onset PD patients and OFF-time as measured by the Movement Disorders Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part IV Sum Score and Part IV item scores. Methods64 individuals with mild-moderate PD (age: M(SD) = 68.72 (8.88)), years with PD: M(SD) = 6.61 (5.05); Hoehn and Yahr stage Med (1st, 3rd quartile) = 2.0 (2.0, 3.0) were assessed with the MDS-UPDRS parts I-IV. We conducted two-tailed independent sample t-tests to examine the differences between PD patients with left versus right onset. ResultsRight onset PD was significantly associated with more overall MRMF (p = 0.01), more OFF-time (p = 0.04), greater impact of motor fluctuations on daily life (p = 0.02) and more complex (unpredictable) MRMF (p = 0.01). ConclusionPeople with right onset PD have more complications with levodopa treatment. Alternative and/or adjuvant treatments to levodopa may be particularly beneficial for those with right onset PD.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antiparkinson Agents - therapeutic use</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Functional Laterality - drug effects</subject><subject>Functional Laterality - physiology</subject><subject>Humans</subject><subject>Levodopa</subject><subject>Levodopa - therapeutic use</subject><subject>Male</subject><subject>MDS-UPDRS</subject><subject>Mental Status and Dementia Tests</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>OFF-time</subject><subject>Parkinson Disease - diagnosis</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson Disease - physiopathology</subject><subject>Parkinson Disease, Secondary - diagnosis</subject><subject>Parkinson's disease</subject><subject>Severity of Illness Index</subject><subject>Side-of-onset</subject><subject>Treatment</subject><issn>0022-510X</issn><issn>1878-5883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ks9u1DAQxiMEokvhAbgg3-CSxY7jxAGpUtXyp1IrKrZFvVlee0K9Tezg8RbtA_DeeNlSAQdOluzv-2Y8vymK54zOGWXN69V85XFeUSbnrJpTWj0oZky2shRS8ofFLN9UpWD0aq94griilDZSdo-LPU4FbxvOZsWPi2sgGjEYp5MLniwhfQfw5FzHG-cx-JdIrEPQCAQ345TCSNBZKENfBo-QiPaWTBD7EEftDZAcknLo2fGivDw__rwgaPQAZNIxkZMvb8hZSCESE8ZpcOZXUXxaPOr1gPDs7twvLt-_uzj6WJ5--nBydHhaGsGrVMquq7ol410nLHS8b2pRs34phGhsy7mwnNqqBdG3S26Npq1tmqatAahp2vxfvl8c7HKn9XIEa8CnqAc1RTfquFFBO_X3i3fX6mu4VQ2v6q6mOeDVXUAM39aASY0ODQyD9hDWqComBGsqwessZTupiQExQn9fhlG1xadWKuNTW3yKVSrDyp4Xf_Z37_jNKwve7gSQp3TrICo0DvLUrYtgkrLB_Tf-4B-3GZzPEIYb2ACuwjr6PH7FFGaDWmz3Z7s-THJaS3nFfwIAbcHW</recordid><startdate>20190115</startdate><enddate>20190115</enddate><creator>Bay, Allison A</creator><creator>Hart, Ariel R</creator><creator>Michael Caudle, W</creator><creator>Corcos, Daniel M</creator><creator>Hackney, Madeleine E</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190115</creationdate><title>The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications</title><author>Bay, Allison A ; Hart, Ariel R ; Michael Caudle, W ; Corcos, Daniel M ; Hackney, Madeleine E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c532t-89929b13995de93f64541fb5556d7335d30d27e5f7b3dca07d66674ee0c677633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antiparkinson Agents - therapeutic use</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Functional Laterality - drug effects</topic><topic>Functional Laterality - physiology</topic><topic>Humans</topic><topic>Levodopa</topic><topic>Levodopa - therapeutic use</topic><topic>Male</topic><topic>MDS-UPDRS</topic><topic>Mental Status and Dementia Tests</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>OFF-time</topic><topic>Parkinson Disease - diagnosis</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson Disease - physiopathology</topic><topic>Parkinson Disease, Secondary - diagnosis</topic><topic>Parkinson's disease</topic><topic>Severity of Illness Index</topic><topic>Side-of-onset</topic><topic>Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bay, Allison A</creatorcontrib><creatorcontrib>Hart, Ariel R</creatorcontrib><creatorcontrib>Michael Caudle, W</creatorcontrib><creatorcontrib>Corcos, Daniel M</creatorcontrib><creatorcontrib>Hackney, Madeleine E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the neurological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bay, Allison A</au><au>Hart, Ariel R</au><au>Michael Caudle, W</au><au>Corcos, Daniel M</au><au>Hackney, Madeleine E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications</atitle><jtitle>Journal of the neurological sciences</jtitle><addtitle>J Neurol Sci</addtitle><date>2019-01-15</date><risdate>2019</risdate><volume>396</volume><spage>262</spage><epage>265</epage><pages>262-265</pages><issn>0022-510X</issn><eissn>1878-5883</eissn><abstract>AbstractIntroductionParkinson's disease (PD) is a neurodegenerative condition associated with aging characterized by loss of dopamine-producing neurons in the substantia nigra pars compacta and a reduction in dopamine levels in the striatum. PD is commonly treated using dopamine-replacement medication called levodopa. Levodopa has decreasing efficacy over time. Periods when levodopa is not effective at controlling symptoms of PD are called “OFF-time” or “medication-related motor fluctuations,” (MRMF). One characteristic of PD is unilateral side of symptom onset. Previous studies have found that side of onset was associated with differential motor and cognitive PD-related symptoms. The main study objective was to examine differences in left and right onset PD patients and OFF-time as measured by the Movement Disorders Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part IV Sum Score and Part IV item scores. Methods64 individuals with mild-moderate PD (age: M(SD) = 68.72 (8.88)), years with PD: M(SD) = 6.61 (5.05); Hoehn and Yahr stage Med (1st, 3rd quartile) = 2.0 (2.0, 3.0) were assessed with the MDS-UPDRS parts I-IV. We conducted two-tailed independent sample t-tests to examine the differences between PD patients with left versus right onset. ResultsRight onset PD was significantly associated with more overall MRMF (p = 0.01), more OFF-time (p = 0.04), greater impact of motor fluctuations on daily life (p = 0.02) and more complex (unpredictable) MRMF (p = 0.01). ConclusionPeople with right onset PD have more complications with levodopa treatment. Alternative and/or adjuvant treatments to levodopa may be particularly beneficial for those with right onset PD.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>30537631</pmid><doi>10.1016/j.jns.2018.12.002</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-510X
ispartof Journal of the neurological sciences, 2019-01, Vol.396, p.262-265
issn 0022-510X
1878-5883
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6324940
source MEDLINE; Elsevier ScienceDirect Journals
subjects Aged
Aged, 80 and over
Antiparkinson Agents - therapeutic use
Disease Progression
Female
Functional Laterality - drug effects
Functional Laterality - physiology
Humans
Levodopa
Levodopa - therapeutic use
Male
MDS-UPDRS
Mental Status and Dementia Tests
Middle Aged
Neurology
OFF-time
Parkinson Disease - diagnosis
Parkinson Disease - drug therapy
Parkinson Disease - physiopathology
Parkinson Disease, Secondary - diagnosis
Parkinson's disease
Severity of Illness Index
Side-of-onset
Treatment
title The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T02%3A43%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20association%20between%20Parkinson's%20disease%20symptom%20side-of-onset%20and%20performance%20on%20the%20MDS-UPDRS%20scale%20part%20IV:%20Motor%20complications&rft.jtitle=Journal%20of%20the%20neurological%20sciences&rft.au=Bay,%20Allison%20A&rft.date=2019-01-15&rft.volume=396&rft.spage=262&rft.epage=265&rft.pages=262-265&rft.issn=0022-510X&rft.eissn=1878-5883&rft_id=info:doi/10.1016/j.jns.2018.12.002&rft_dat=%3Cproquest_pubme%3E2155162534%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2155162534&rft_id=info:pmid/30537631&rft_els_id=S0022510X1830488X&rfr_iscdi=true